Cantargia AB

ST:CANTA Sweden Biotechnology
Market Cap
$86.21 Million
Skr967.10 Million SEK
Market Cap Rank
#19348 Global
#199 in Sweden
Share Price
Skr3.89
Change (1 day)
-3.83%
52-Week Range
Skr1.03 - Skr6.20
All Time High
Skr58.00
Categories
Companies in Sweden Biotechnology
About

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more

Cantargia AB (CANTA) - Net Assets

Latest net assets as of September 2025: Skr297.57 Million SEK

Based on the latest financial reports, Cantargia AB (CANTA) has net assets worth Skr297.57 Million SEK as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr358.89 Million) and total liabilities (Skr61.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets Skr297.57 Million
% of Total Assets 82.92%
Annual Growth Rate 39.44%
5-Year Change -86.96%
10-Year Change 314.56%
Growth Volatility 240.14

Cantargia AB - Net Assets Trend (2011–2024)

This chart illustrates how Cantargia AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Cantargia AB (2011–2024)

The table below shows the annual net assets of Cantargia AB from 2011 to 2024.

Year Net Assets Change
2024-12-31 Skr116.30 Million -31.08%
2023-12-31 Skr168.74 Million -56.70%
2022-12-31 Skr389.68 Million -26.85%
2021-12-31 Skr532.75 Million -40.27%
2020-12-31 Skr891.93 Million +526.92%
2019-12-31 Skr142.27 Million -8.24%
2018-12-31 Skr155.04 Million -37.00%
2017-12-31 Skr246.12 Million +562.91%
2016-12-31 Skr37.13 Million +32.34%
2015-12-31 Skr28.05 Million +584.70%
2014-12-31 Skr4.10 Million +30.84%
2013-12-31 Skr3.13 Million +1.77%
2012-12-31 Skr3.08 Million +99.51%
2011-12-31 Skr1.54 Million --

Equity Component Analysis

This analysis shows how different components contribute to Cantargia AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 167671241600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock Skr14.70 Million 12.63%
Other Comprehensive Income Skr5.19 Million 4.47%
Other Components Skr1.78 Billion 1528.24%
Total Equity Skr116.30 Million 100.00%

Cantargia AB Competitors by Market Cap

The table below lists competitors of Cantargia AB ranked by their market capitalization.

Company Market Cap
IGM Biosciences Inc
NASDAQ:IGMS
 		$76.57 Million
AQUILA ACQ.CORP. CL.A
F:T81
 		$76.58 Million
Hanla IMS Co. Ltd
KQ:092460
 		$76.58 Million
AME Elite Consortium Bhd
KLSE:5293
 		$76.60 Million
Kish Bancorp Inc
OTCQX:KISB
 		$76.56 Million
K-Fast Holding AB (publ)
ST:KFAST-B
 		$76.54 Million
ZHOU HEI YA HLDG -000001
F:ZHY
 		$76.53 Million
Musti Group Oyj
HE:MUSTI
 		$76.52 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Cantargia AB's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 168,742,000 to 116,304,000, a change of -52,438,000 (-31.1%).
  • Net loss of 161,654,000 reduced equity.
  • Other comprehensive income increased equity by 5,194,000.
  • Other factors increased equity by 104,022,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income Skr-161.65 Million -138.99%
Other Comprehensive Income Skr5.19 Million +4.47%
Other Changes Skr104.02 Million +89.44%
Total Change Skr- -31.08%

Book Value vs Market Value Analysis

This analysis compares Cantargia AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 6.14x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 43.02x to 6.14x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2011-12-31 Skr0.09 Skr3.89 x
2012-12-31 Skr0.18 Skr3.89 x
2013-12-31 Skr0.18 Skr3.89 x
2014-12-31 Skr0.24 Skr3.89 x
2015-12-31 Skr1.63 Skr3.89 x
2016-12-31 Skr1.67 Skr3.89 x
2017-12-31 Skr6.32 Skr3.89 x
2018-12-31 Skr1.95 Skr3.89 x
2019-12-31 Skr1.66 Skr3.89 x
2020-12-31 Skr8.30 Skr3.89 x
2021-12-31 Skr5.32 Skr3.89 x
2022-12-31 Skr3.04 Skr3.89 x
2023-12-31 Skr0.99 Skr3.89 x
2024-12-31 Skr0.63 Skr3.89 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Cantargia AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -138.99%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 1.47x
  • Recent ROE (-138.99%) is below the historical average (-115.83%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 -219.72% 0.00% 0.00x 1.56x Skr-3.54 Million
2012 -112.60% 0.00% 0.00x 1.23x Skr-3.77 Million
2013 -253.73% 0.00% 0.00x 1.27x Skr-8.26 Million
2014 -204.27% 0.00% 0.00x 4.91x Skr-8.78 Million
2015 -61.27% 0.00% 0.00x 1.12x Skr-20.00 Million
2016 -120.34% 0.00% 0.00x 1.28x Skr-48.39 Million
2017 -24.48% 0.00% 0.00x 1.12x Skr-84.86 Million
2018 -58.80% 0.00% 0.00x 1.11x Skr-106.66 Million
2019 -77.88% 0.00% 0.00x 1.17x Skr-125.04 Million
2020 -19.41% 0.00% 0.00x 1.04x Skr-262.28 Million
2021 -68.80% 0.00% 0.00x 1.13x Skr-419.78 Million
2022 -95.41% 0.00% 0.00x 1.22x Skr-410.78 Million
2023 -165.95% 0.00% 0.00x 1.33x Skr-296.90 Million
2024 -138.99% 0.00% 0.00x 1.47x Skr-173.28 Million

Industry Comparison

This section compares Cantargia AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $60,327,288
  • Average return on equity (ROE) among peers: -132.31%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Cantargia AB (CANTA) Skr297.57 Million -219.72% 0.21x $76.57 Million
2cureX AB (2CUREX) $20.24 Million -15.50% 0.13x $1.38 Million
Abliva AB (ABLI) $63.04 Million -23.59% 0.13x $46.60 Million
Ascelia Pharma AB (publ) (ACE) $180.86 Million -72.56% 0.21x $25.35 Million
AcouSort AB (ACOU) $20.11 Million -65.68% 1.12x $4.82 Million
Active Biotech AB (ACTI) $162.30 Million -107.35% 0.93x $3.55 Million
Alzinova AB (ALZ) $29.39 Million -8.53% 0.08x $4.19 Million
AlzeCure Pharma (ALZCUR) $110.75 Million -64.44% 0.06x $12.56 Million
Annexin Pharmaceuticals AB (ANNX) $20.64 Million -216.80% 0.22x $4.92 Million
Alligator Bioscience AB (ATORX) $6.86 Million -748.65% 15.13x $723.60K
Biosergen AS (BIOSGN) $-10.92 Million 0.00% 0.00x $2.76 Million